Substance P (SP) is a neuropeptide belonging to the family of tachykinins. It acts in the central nervous system (CNS) as a neurotransmitter, neuromodulator, and neurotrophic factor binding the G-protein-coupled receptor NK1, which is the tachykinins receptors' form predominant in the brain. The expression of SP is particularly high in nervous structures critically involved in pathogenesis of Parkinson's disease (PD), including the enteric nervous system, the vagus nerve, the autonomic centers, the neocortex and the limbic areas, and, especially, the substantia nigra. In theory, the levels of SP might reflect neurodegeneration in these systems, thus representing a potential, ideal biomarker for PD. However, although many studies explored the dynamics of SP modulation in PD animal models, data from patients are still not available.

Serum substance P is increased in Parkinson's disease and correlates with motor impairment / Schirinzi, T.; Maftei, D.; Ralli, M.; Greco, A.; Mercuri, N. B.; Lattanzi, R.; Severini, C.. - In: MOVEMENT DISORDERS. - ISSN 0885-3185. - 37:1(2022), pp. 228-230. [10.1002/mds.28824]

Serum substance P is increased in Parkinson's disease and correlates with motor impairment

Maftei D.
Secondo
;
Ralli M.;Greco A.;Lattanzi R.
Penultimo
;
2022

Abstract

Substance P (SP) is a neuropeptide belonging to the family of tachykinins. It acts in the central nervous system (CNS) as a neurotransmitter, neuromodulator, and neurotrophic factor binding the G-protein-coupled receptor NK1, which is the tachykinins receptors' form predominant in the brain. The expression of SP is particularly high in nervous structures critically involved in pathogenesis of Parkinson's disease (PD), including the enteric nervous system, the vagus nerve, the autonomic centers, the neocortex and the limbic areas, and, especially, the substantia nigra. In theory, the levels of SP might reflect neurodegeneration in these systems, thus representing a potential, ideal biomarker for PD. However, although many studies explored the dynamics of SP modulation in PD animal models, data from patients are still not available.
2022
Parkinson's disease; motor disorders; neuropsychological tests; substance P
01 Pubblicazione su rivista::01f Lettera, Nota
Serum substance P is increased in Parkinson's disease and correlates with motor impairment / Schirinzi, T.; Maftei, D.; Ralli, M.; Greco, A.; Mercuri, N. B.; Lattanzi, R.; Severini, C.. - In: MOVEMENT DISORDERS. - ISSN 0885-3185. - 37:1(2022), pp. 228-230. [10.1002/mds.28824]
File allegati a questo prodotto
File Dimensione Formato  
Schirinzi_Serum substance_2022.pdf

solo gestori archivio

Note: Schirinzi_Serum substance_2022
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 219.54 kB
Formato Adobe PDF
219.54 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1643921
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact